Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application ...

This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been accepted for priority review by the US Food and Drug Administration (FDA ...